Newfoundland and Labrador biotechnology company Sequence Bio is pleased to announce that Brendan Paddick, Chief Executive Officer of Columbus Capital, has led an investment round in the company and been appointed to its board of directors.
Sequence Bio is researching Newfoundland and Labrador’s genetically distinct founder population to accelerate the development of new medicines and disease treatments. The pathway to potentially important genetic discoveries is complex and requires significant investments in cutting-edge analysis technologies, a diverse range of highly specialized skills, and in partnerships with global drug developers to help produce better and safer therapeutics, faster. This financing will support Sequence Bio through its next phase of growth in these areas, and with the continued expansion of the pilot phase its flagship research study, the NL Genome Project, throughout the province.
Chris Gardner, CEO of Sequence Bio said, “Sequence Bio is tackling a global shortage of drug targets that can significantly increase the success rate of new therapeutics. We have the right mix of Newfoundland and Labrador and industry investors to advance our commitment to returning benefits back to the province, while also leveraging the expertise of those who have helped grow some of the world's most impactful deep tech and life sciences companies.” He continued, “As someone who has built an international reputation on changing the status quo, Brendan will feel at home on a team that truly believes in our ability to transform a drug discovery process that is ripe for innovation.”
Brendan Paddick is a highly accomplished executive, corporate director, and philanthropist with deep capital markets and governance experience. He is the CEO of Columbus Capital, and has held a number of senior executive and director positions with large private companies and public companies listed on the TSX, London Stock Exchange (FTSE), Nasdaq, and the Bahamas Stock Exchange (BISX), including MDA Space (TSX), a global space industry leader developing custom technology solutions in geo-intelligence, robotics, and space operations, including the iconic CanadArm.
“Purposeful companies with the potential to improve lives are rare, and I’m proud to play a part in helping Sequence Bio realize that potential.” says Brendan. “The team is passionate, mission-driven, and at the forefront of real innovation - all critical traits of organizations with the opportunity to affect meaningful change. At Columbus we have a simple mission: Don’t predict the future, enable it. Sequence Bio fits that mission and I’m excited about what we can, and will, accomplish together.”
In addition, John Phillips of Klister has joined Brendan, Mark Dobbin, and Chris Gardner on Sequence Bio’s Board of Directors.
Chairperson of Sequence Bio’s Board of Directors, Mark Dobbin, adds “Sequence Bio is truly at an inflection point, and I am delighted to welcome both Brendan and John to our board. Their complementary skills and experiences in scaling world leading companies will play an important role in Sequence Bio’s continued success.”
Sequence Bio is a Newfoundland and Labrador biotechnology company leading the NL Genome Project to research the unique genetic makeup of our province to discover better, safer medicines and improve how we treat and prevent diseases. We are a committed team of local leaders and international experts driven to make a difference and benefit the lives of Newfoundlanders and Labradorians and others around the world for generations to come.
Learn more at SequenceBio.com and NLGenomeProject.ca
VP, Market Development
Note: Sequence Bio does not release any of the terms of its financings.